|
1
|
Stupphann D, Rauner M, Krenbek D, Patsch
J, Pirker T, Muschitz C, Resch H and Pietschmann P: Intracellular
and surface RANKL are differentially regulated in patients with
ankylosing spondylitis. Rheumatol Int. 28:987–993. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mattey DL, Packham JC, Nixon NB, Coates L,
Creamer P, Hailwood S, Taylor GJ and Bhalla AK: Association of
cytokine and matrix metalloproteinase profiles with disease
activity and function in ankylosing spondylitis. Arthritis Res
Ther. 14:R1272012. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siebuhr AS, Wang J, Karsdal M and
Bay-Jensen ACYJQZ: Matrix metalloproteinase-dependent turnover of
cartilage, synovial membrane, and connective tissue is elevated in
rats with collagen induced arthritis. J Transl Med. 10:1952012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hu Z, Lin D, Qi J, Qiu M, Lv Q, Li Q, Lin
Z, Liao Z, Pan Y, Jin O, et al: Serum from patients with ankylosing
spondylitis can increase PPARD, fra-1, MMP7, OPG and RANKL
expression in MG63 cells. Clinics (Sao Paulo). 70:738–742. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Raju R, Balakrishnan L, Nanjappa V,
Bhattacharjee M, Getnet D, Muthusamy B, Thomas Kurian J, Sharma J,
Rahiman BA, Harsha HC, et al: A comprehensive manually curated
reaction map of RANKL/RANK-signaling pathway. Database (Oxford).
2011:bar0212011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mou YK, Zhang PP, Li QX, Lin ZM, Liao ZT,
Wei QJ and Gu JR: Changes of serum levels of MMP-3, sRANKL, and OPG
in juvenile-onset ankylosing spondylitis patients carrying
different HLA-B27 subtypes. Clin Rheumatol. 34:1085–1089. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Barrett E, Brothers S, Wahlestedt C and
Beurel E: I-BET151 selectively regulates IL-6 production. Biochim
Biophys Acta. 1842:1549–1555. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lamoureux F, Baud'huin M, Calleja
Rodriguez L, Jacques C, Berreur M, Rédini F, Lecanda F, Bradner JE,
Heymann D and Ory B: Selective inhibition of BET bromodomain
epigenetic signalling interferes with the bone-associated tumour
vicious cycle. Nat Commun. 5:35112014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chaidos A, Caputo V, Gouvedenou K, Liu B,
Marigo I, Chaudhry MS, Rotolo A, Tough DF, Smithers NN, Bassil AK,
et al: Potent antimyeloma activity of the novel bromodomain
inhibitors I-BET151 and I-BET762. Blood. 123:697–705. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Parkmin KH, Lim E, Lee MJ, Park SH,
Giannopoulou E, Yarilina A, van der Meulen M, Zhao B, Smithers N,
Witherington J, et al: Inhibition of osteoclastogenesis and
inflammatory bone resorption by targeting BET proteins and
epigenetic regulation. Nat Commun. 5:54182013. View Article : Google Scholar
|
|
11
|
Zochling J and Braun J: Assessments in
ankylosing spondylitis. Best Pract Res Clin Rheumatol. 21:699–712.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Calin A, Garrett S, Whitelock H, Kennedy
LG, O'Hea J, Mallorie P and Jenkinson T: A new approach to defining
functional ability in ankylosing spondylitis: The development of
the Bath Ankylosing Spondylitis Functional Index. J Rheumatol.
21:2281–2285. 1994.PubMed/NCBI
|
|
13
|
Li X, He L, Hu Y, Duan H, Li X, Tan S, Zou
M, Gu C, Zeng X, Yu L, et al: Sinomenine suppresses osteoclast
formation and Mycobacterium tuberculosis H37Ra-induced bone loss by
modulating RANKL signaling pathways. PLoS One. 8:e742742013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
He L, Duan H and Li X, Wang S, Zhang Y,
Lei L, Xu J, Liu S and Li X: Sinomenine down-regulates TLR4/TRAF6
expression and attenuates lipopolysaccharide-induced
osteoclastogenesis and osteolysis. Eur J Pharmacol. 779:66–79.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lin P, Bach M, Asquith M, Lee AY,
Akileswaran L, Stauffer P, Davin S, Pan Y, Cambronne ED, Dorris M,
et al: HLA-B27 and human β2-microglobulin affect the gut microbiota
of transgenic rats. PLoS One. 9:e1056842014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rysnik O, McHugh K, van Duivenvoorde L,
van Tok M, Taurog J, Kollnberger S, Baeten D and Bowness P: Data
showing non-conventional HLA-B27 expression in axial joints and gut
tissue from B27 transgenic rats, and in frozen and paraffin-fixed
synovial SpA tissue. Data Brief. 9:100–111. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Atkinson SM, Bleil J, Maier R, Kühl AA,
Thorn M, Serikawa K, Fox B, Kruse K, Haase C, Skov S, et al:
Anti-RANKL treatment inhibits erosive joint destruction and lowers
inflammation but has no effect on bone formation in the
delayed-type hypersensitivity arthritis (DTHA) model. Arthritis Res
Ther. 18:282016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Reveille JD: Biomarkers for diagnosis,
monitoring of progression, and treatment responses in ankylosing
spondylitis and axial spondyloarthritis. Clin Rheumatol.
34:1009–1018. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Baud'huin M, Lamoureux F, Jacques C,
Calleja Rodriguez L, Quillard T, Charrier C, Amiaud J, Berreur M,
Brounais-LeRoyer B, Owen R, et al: Inhibition of BET proteins and
epigenetic signaling as a potential treatment for osteoporosis.
Bone. 94:10–21. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shaw AT and Gravallese EM: Mediators of
inflammation and bone remodeling in rheumatic disease. Semin Cell
Dev Biol. 49:2–10. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Im CH, Kang EH, Ki JY, Shin DW, Choi HJ,
Chang EJ, Lee EY, Lee YJ, Lee EB, Kim HH and Song YW: Receptor
activator of nuclear factor kappa B ligand-mediated
osteoclastogenesis is elevated in ankylosing spondylitis. Clin Exp
Rheumatol. 27:620–625. 2009.PubMed/NCBI
|
